ISRCTN99599132已完成不适用
A randomised, partially double-blind, controlled, parallel group study to evaluate the efficacy, safety and tolerability of pumactant 240mg in the prevention of the formation of peritoneal adhesions following abdominal surgery
Research and Innovation Service, University of Dundee (UK)0 个研究点目标入组 140 人开始时间: 2011年3月31日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Male and female subjects ( > 18 years old) were recruited into the study if it was thought that at the primary surgical procedure, they required the formation of a temporary stoma
- •2. Patients undergoing emergency treatment of obstructed /perforated carcinoma of the bowel or colonic diverticulitis by Hartmanns procedure
- •3. Patients undergoing elective low anterior bowel resection for the treatment of rectal carcinoma requiring formation of a temporary ileostomy
排除标准
- •1. Patients unable to comply with the study requirements, had cognitive impairments, had a history of drug and / or alcohol abuse
- •2. Patients receiving steroid medication
- •3. Patients had metastatic disease
- •4. Patients had American Society of Anesthesiologists (ASA) fitness grade of IV or above
- •5. Pregnant or lactating females
研究者
相似试验
已完成
2 期
A randomized, double-blinded, parallel-controlled, dose exploratory, multicentered-phase II clinical trial for the safety and effectiveness of hydroxysafflor yellow A (HSYA) injection in the treatment of&Acute atherosclerotic thrombotic cerebral infarctionITMCTR2000002982Guangdong Hospital of traditional Chinese Medicine
尚未招募
4 期
A multi-center clinical trial to evaluate the efficacy and safety of Kangbingdu Granulesin the treatment of influenzainfluenzaITMCTR1900002747China-Japan Friendship Hospital
进行中（未招募）
不适用
A controlled, randomised, double-blind, double-dummy, parallel-group, phase III, multicenter study to evaluate efficacy and safety of the oral direct thrombin inhibitor AZD0837 compared to warfarin for the prevention of stroke and systemic embolic events (SEE) in patients with atrial fibrillation (ASSURE-AF) - ASSURE-AFthe prevention of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (AF)MedDRA version: 9.1Level: LLTClassification code 10003658Term: Atrial fibrillationEUCTR2008-003698-42-DKAstraZeneca AB14,600
进行中（未招募）
不适用
A controlled, randomised, double-blind, double-dummy, parallel-group, phase III, multicenter study to evaluate efficacy and safety of the oral direct thrombin inhibitor AZD0837 compared to warfarin for the prevention of stroke and systemic embolic events (SEE) in patients with atrial fibrillation (ASSURE-AF) - ASSURE-AFEUCTR2008-003698-42-SEAstraZeneca AB14,600
进行中（未招募）
不适用
A controlled, randomised, double-blind, double-dummy, parallel-group, phase III, multicenter study to evaluate efficacy and safety of the oral direct thrombin inhibitor AZD0837 compared to warfarin for the prevention of stroke and systemic embolic events (SEE) in patients with atrial fibrillation (ASSURE-AF) - ASSURE-AFEUCTR2008-003698-42-BGAstraZeneca AB14,600